Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

NEXT STORY
Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer
PREV STORY
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biocartis Group NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION29 October 2018, 07:00 CET Disclosure of a transparency notification Mechelen, ...

author_avatar
NASDAQ Market News

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

author_avatar
NASDAQ Market News

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm

author_avatar
NASDAQ Market News